Micah Anderson
Chief Executive Officer at LEEF BRANDS INC.
Net worth: 2 M $ as of 29/04/2024
Micah Anderson active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LEEF BRANDS INC. | Director/Board Member | 05/09/2022 | - |
| Chief Executive Officer | 05/09/2022 | - | |
Leef Holdings, Inc.
 Leef Holdings, Inc. Agricultural Commodities/MillingProcess Industries Leef Holdings, Inc. provides investment services. The company was founded in 2019 and is headquartered in La Jolla, CA. | Chief Executive Officer | - | - |
| Chairman | - | - | |
| Founder | - | - | |
Aya Biosciences, Inc.
 Aya Biosciences, Inc. BiotechnologyHealth Technology Aya Biosciences, Inc. is a neuroscience company that is dedicated to improving the mental health and well-being of patients with neuropsychiatric diseases. The company is based in La Jolla, CA. The company is creating a pipeline of novel, orally active serotonin receptor agonists as a new class of therapeutics. The CEO of the company is Micah Anderson. | Director/Board Member | - | - |
| Chief Executive Officer | - | - |
Career history of Micah Anderson
Statistics
International
| United States | 3 |
| Canada | 2 |
Operational
| Chief Executive Officer | 3 |
| Director/Board Member | 2 |
| Chairman | 1 |
Sectoral
| Process Industries | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| LEEF BRANDS INC. | Process Industries |
| Private companies | 2 |
|---|---|
Leef Holdings, Inc.
Leef Holdings, Inc. Agricultural Commodities/MillingProcess Industries Leef Holdings, Inc. provides investment services. The company was founded in 2019 and is headquartered in La Jolla, CA. | Process Industries |
Aya Biosciences, Inc.
Aya Biosciences, Inc. BiotechnologyHealth Technology Aya Biosciences, Inc. is a neuroscience company that is dedicated to improving the mental health and well-being of patients with neuropsychiatric diseases. The company is based in La Jolla, CA. The company is creating a pipeline of novel, orally active serotonin receptor agonists as a new class of therapeutics. The CEO of the company is Micah Anderson. | Health Technology |
- Stock Market
- Insiders
- Micah Anderson
- Experience
